Evidence map›Paper›PMID 39061034›Full record

ArticleBMC public health2024

Association between glucose levels and all-cause mortality in cancer survivors: findings from NHANES 1999-2018.

Jing Xie, Zeye Liu, Wanlu Ma, Liqun Ren, Liyun He, Shan Lu, Xiangzhi Meng, Ruibing Xia, Yun Liu, Naifeng Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jing Xie *Department of Pharmacy, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
Zeye Liu *Department of Cardiac Surgery, Peking University People's Hospital, Peking University, Beijing, China.
Wanlu MaDepartment of Endocrinology, China-Japan Friendship Hospital, Beijing, China.
Liqun RenDepartment of Gerontology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
Liyun HeDepartment of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Shan LuDepartment of Geriatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Xiangzhi MengDepartment of Thoracic Surgical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ruibing XiaDepartment of Medicine, University Hospital Munich, Ludwig-Maximilians-University Munich (LMU), Munich, Germany.
Yun LiuDepartment of Information, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China. liuyun@njmu.edu.cn.
Naifeng LiuDepartment of Pharmacy, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China. liunf@seu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperglycemia is a rapidly increasing risk factor for cancer mortality worldwide. However, the dose‒response relationship between glucose levels and all-cause mortality in cancer survivors is still uncertain.

methodsWe enrolled 4,491 cancer survivors (weighted population 19,465,739) from the 1999-2019 National Health and Nutrition Examination Survey (NHANES). Cancer survivors were defined based on the question of whether they had ever been diagnosed with cancer by a doctor or a health professional. Hemoglobin A1c (HbA1c) was selected in this study as a stable marker of glucose level. Mortality was ascertained by linkage to National Death Index records until December 31, 2019. Cox proportional hazard, Kaplan‒Meier survival curves and Restricted cubic spline regression models were used to evaluate the associations between HbA1c and all-cause mortality risk in cancer survivors.

resultsIn NHANES, after adjusting for confounders, HbA1c had an independent nonlinear association with increased all-cause mortality in cancer survivors (nonlinear P value < 0.05). The threshold value for HbA1c was 5.4%, and the HRs (95% CI) below and above the threshold value were 0.917 (0.856,0.983) and 1.026 (1.010,1.043), respectively. Similar associations were found between fasting glucose and all-cause mortality in cancer survivors, and the threshold value was 5.7 mmol/L.

conclusionsHbA1c was nonlinearly associated with all-cause mortality in cancer survivors, and the critical value of HbA1c in decreased mortality was 5.4%, suggesting optimal glucose management in cancer survivors may be a key to preventing premature death in cancer survivors.

Indexed as

Blood GlucoseCancer SurvivorsGlycated HemoglobinNutrition SurveysAdultAgedCause of DeathFemaleHumansHyperglycemiaMaleMiddle AgedNeoplasmsProportional Hazards ModelsRisk FactorsUnited StatesBlood GlucoseGlycated HemoglobinAll-cause mortalityCancer survivorsFasting glucoseHbA1cNHANES

Identifiers

PMID39061034
PMCPMC11282799

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.